TD Cowen analyst Charles Rhyee lowered the firm’s price target on Medpace (MEDP) to $356 from $366 and keeps a Sell rating on the shares. The firm said although the demand environment for CRO has stabilized they do not believe consensus fully reflects the impact of lower-than-normal B2Bs in 1H25, likely to persist into 2H25, on 2026 revenue and adjusted EBITDA growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDP: